JUVAR
MCID: JVN061
MIFTS: 60

Juvenile Arthritis (JUVAR)

Categories: Bone diseases, Genetic diseases, Immune diseases, Liver diseases

Aliases & Classifications for Juvenile Arthritis

MalaCards integrated aliases for Juvenile Arthritis:

Name: Juvenile Arthritis 56 73 42 32
Juvenile Idiopathic Arthritis 73 36 17
Arthritis, Juvenile 74 43
Juvar 56 73
Juvenile Chronic Arthritis 73

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive

Miscellaneous:
clinical variability, inter- and intrafamilial
intermittent fever persists in some patients
arthritis may be episodic in some patients
organomegaly (hepatomegaly/splenomegaly, in some patients)
patients may develop contractures in affected joints
remission may be difficult to achieve


HPO:

31
juvenile arthritis:
Inheritance autosomal recessive inheritance
Onset and clinical course childhood onset


Classifications:



Summaries for Juvenile Arthritis

KEGG : 36 Juvenile idiopathic arthritis (JIA) is one of the most common childhood rheumatic diseases. Clinically, it is defined as arthritis of unknown origin that starts before the age of 16, and persists for at least 6 weeks. Next to a certain genetic predisposition, environmental factors play a role leading to a chronic inflammatory response. JIA is not a single disorder but consists of a heterogeneous group of auto-immune inflammatory diseases. It has variable rates in course and activity of disease. Based on 6 months of clinical symptoms and global prognostic factors, the following clinical subtypes of JIA are recognized: systemic JIA, oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic JIA, enthesitis- related arthritis, and undifferentiated arthritis. Systemic JIA, also known as Still's disease, is a subtype with strong systemic clinical symptoms. Patients with systemic JIA have, in addition to arthritis, prominent symptoms of systemic inflammation such as spiking fever, rash, pericarditis, peritonitis, lymphadenopathy and organomegaly. A severe and often life-threatening complication occurring in 10-30% of patients with systemic JIA is macrophage activation syndrome. Polymorphisms in the IL6 and in the MIF gene have been found to be associated with susceptibility to the disorder. Based on the known relevance of IL6 in JIA pathophysiology, tocilizumab has been investigated and approved for use in the treatment of systemic and polyarticular JIA.

MalaCards based summary : Juvenile Arthritis, also known as juvenile idiopathic arthritis, is related to rheumatoid arthritis, systemic juvenile and juvenile rheumatoid arthritis. An important gene associated with Juvenile Arthritis is LACC1 (Laccase Domain Containing 1), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs Naproxen and Esomeprazole have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and testes, and related phenotypes are arthritis and fever

OMIM : 56 Juvenile arthritis (JUVAR) is characterized by onset in early childhood of symmetric arthritis in multiple joints, associated with a marked increase in inflammatory markers. Some patients exhibit systemic symptoms, including quotidian fever, erythematous rash, generalized lymphadenopathy, hepatomegaly, and/or splenomegaly. There is high clinical variability, even within the same family (Karacan et al., 2018). (618795)

MedlinePlus : 42 Juvenile arthritis (JA) is arthritis that happens in children. It causes joint swelling, pain, stiffness, and loss of motion. It can affect any joint, but is more common in the knees, hands, and feet. In some cases it can affect internal organs as well. The most common type of JA that children get is juvenile idiopathic arthritis. There are several other forms of arthritis affecting children. One early sign of JA may be limping in the morning. Symptoms can come and go. Some children have just one or two flare-ups. Others have symptoms that never go away. JA can cause growth problems and eye inflammation in some children. No one knows exactly what causes JA. Most types are autoimmune disorders. This means that your immune system, which normally helps your body fight infection, attacks your body's own tissues. JA can be hard to diagnose. Your health care provider may do a physical exam, lab tests, and x-rays. A team of providers usually treats JA. Medicines and physical therapy can help maintain movement and reduce swelling and pain. They may also help prevent and treat complications. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

UniProtKB/Swiss-Prot : 73 Juvenile arthritis: A common inflammatory articular disorder with onset in childhood. It is characterized by chronic joint inflammation causing swelling, pain, stiffness and restricted joint movement. JUVAR has high clinical variability. Some patients exhibit systemic symptoms, including quotidian fever, erythematous rash, generalized lymphadenopathy, hepatomegaly, and/or splenomegaly. The etiology of juvenile arthritis is generally multifactorial, involving both genetic and environmental factors. Familial forms with autosomal recessive inheritance have been reported.

Wikipedia : 74 Juvenile idiopathic arthritis (JIA), is the most common, chronic rheumatic disease of childhood,... more...

Related Diseases for Juvenile Arthritis

Diseases in the Arthritis family:

Juvenile Arthritis Transient Arthritis

Diseases related to Juvenile Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 845)
# Related Disease Score Top Affiliating Genes
1 rheumatoid arthritis, systemic juvenile 33.0 MIF LACC1 IL6
2 juvenile rheumatoid arthritis 31.1 MIF LACC1 IL6 IL1R1 IL10 DEK
3 idiopathic anterior uveitis 31.0 IL6 CXCL8
4 septic arthritis 30.8 IL6 CXCL8 CRP
5 kawasaki disease 30.7 IL6 IL10 CRP
6 hemophagocytic lymphohistiocytosis 30.6 IL10 CXCL8 CR2
7 chickenpox 30.5 IL6 IL10 CRP
8 fasciitis 30.4 IL6 CXCL8 CRP
9 arthritis 30.3 MIF LACC1 IL6 IL1R1 IL10 CXCL8
10 brucellosis 30.3 IL6 IL10 CXCL8 CRP
11 conjunctivitis 30.3 IL6 IL10 CXCL8
12 osteomyelitis 30.2 IL6 IL10 CXCL8
13 synovitis 30.2 IL6 CXCL8 CRP
14 pustulosis of palm and sole 30.1 CXCL8 CRP
15 aggressive periodontitis 30.1 IL6 IL10 CXCL8
16 neutrophilia, hereditary 30.1 IL6 CSF2 CRP
17 mumps 30.1 IL6 IL10 CXCL8
18 pharyngitis 30.1 IL6 CXCL8 CSF2 CRP
19 tenosynovitis 30.1 IL6 CRP
20 spondylitis 30.1 IL6 IL10 CRP
21 chondromalacia 30.1 IL6 CRP
22 bacterial conjunctivitis 30.0 CXCL8 CRP
23 necrotizing fasciitis 30.0 IL6 CXCL8 CRP
24 endophthalmitis 30.0 IL6 CXCL8 CRP
25 periodontitis 30.0 IL6 IL10 CXCL8 CRP
26 iridocyclitis 30.0 IL6 IL10 DEK CRP
27 gingivitis 30.0 IL6 IL10 CXCL8
28 arthropathy 30.0 IL6 IL1RAPL2 CRP
29 rubella 30.0 IL6 IL10 HLA-A
30 herpes zoster 30.0 IL10 HLA-A CRP
31 crohn's disease 30.0 LACC1 IL6 IL10 CXCL8 CRP
32 gingival overgrowth 30.0 IL6 CXCL8 CD36
33 tonsillitis 29.9 IL6 IL10 CXCL8
34 sclerosing cholangitis 29.8 IL6 IL10 CXCL8
35 urethritis 29.8 IL6 CXCL8 CRP
36 cryoglobulinemia 29.8 IL6 IL10 CR2
37 urticaria 29.8 IL6 IL10 FCER2 CRP
38 food allergy 29.8 IL10 FCER2 CXCL8
39 cryopyrin-associated periodic syndrome 29.8 IL6 IL1R1 CRP
40 thrombocytosis 29.8 IL6 CSF2 CRP
41 hypopyon 29.8 IL6 IL10 CRP
42 pericarditis 29.8 IL6 CXCL8 CRP
43 spondyloarthropathy 29.8 IL6 IL10 HLA-A
44 autoimmune hepatitis 29.8 IL6 IL10 HLA-A
45 cytomegalovirus infection 29.8 IL6 HLA-A CXCL8
46 graft-versus-host disease 29.7 IL6 IL10 HLA-A
47 chronic granulomatous disease 29.7 LACC1 IL1RAPL2 CXCL8 CSF2
48 drug-induced lupus erythematosus 29.7 IL6 IL10 CXCL8
49 cholangitis 29.7 IL6 IL10 CXCL8 CRP
50 endocarditis 29.7 IL6 IL10 CXCL8 CRP

Graphical network of the top 20 diseases related to Juvenile Arthritis:



Diseases related to Juvenile Arthritis

Symptoms & Phenotypes for Juvenile Arthritis

Human phenotypes related to Juvenile Arthritis:

31 (show all 26)
# Description HPO Frequency HPO Source Accession
1 arthritis 31 hallmark (90%) HP:0001369
2 fever 31 hallmark (90%) HP:0001945
3 arthralgia 31 hallmark (90%) HP:0002829
4 autoimmunity 31 hallmark (90%) HP:0002960
5 joint stiffness 31 frequent (33%) HP:0001387
6 malabsorption 31 frequent (33%) HP:0002024
7 generalized hyperkeratosis 31 frequent (33%) HP:0005595
8 skin rash 31 frequent (33%) HP:0000988
9 psoriasiform dermatitis 31 frequent (33%) HP:0003765
10 joint dislocation 31 frequent (33%) HP:0001373
11 abdominal pain 31 frequent (33%) HP:0002027
12 joint swelling 31 frequent (33%) HP:0001386
13 uveitis 31 frequent (33%) HP:0000554
14 mediastinal lymphadenopathy 31 frequent (33%) HP:0100721
15 cartilage destruction 31 frequent (33%) HP:0100773
16 abnormality of the sacroiliac joint 31 frequent (33%) HP:0100781
17 nail pits 31 frequent (33%) HP:0001803
18 abnormal fingernail morphology 31 frequent (33%) HP:0001231
19 abnormal pleura morphology 31 frequent (33%) HP:0002103
20 splenomegaly 31 occasional (7.5%) HP:0001744
21 hepatomegaly 31 occasional (7.5%) HP:0002240
22 pericardial effusion 31 occasional (7.5%) HP:0001698
23 leukocytosis 31 very rare (1%) HP:0001974
24 thrombocytosis 31 very rare (1%) HP:0001894
25 antinuclear antibody positivity 31 very rare (1%) HP:0003493
26 periodic fever 31 very rare (1%) HP:0032323

Symptoms via clinical synopsis from OMIM:

56
Hematology:
leukocytosis
thrombocytosis

Abdomen Spleen:
splenomegaly (in some patients)

Growth Other:
failure to thrive, severe (in some patients)

Skeletal Spine:
arthritis of cervical spine

Skeletal Hands:
symmetric erosive arthritis of multiple small joints

Skin Nails Hair Skin:
erythematous maculopapular rash (in some patients) erysipelas-like plaques on legs, recurrent (rare)

Immunology:
generalized lymphadenopathy
elevated markers of inflammation

Cardiovascular Heart:
pericarditis (rare)

Skeletal Skull:
symmetric erosive arthritis of temporomandibular joints

Skeletal Limbs:
symmetric erosive arthritis of multiple large joints
tenosynovitis (in some patients)
serositis (in some patients)

Skeletal Feet:
symmetric erosive arthritis of multiple small joints

Metabolic Features:
fever, quotidian (in some patients)

Clinical features from OMIM:

618795

MGI Mouse Phenotypes related to Juvenile Arthritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.96 CD36 CR2 CSF2 FCER2 HLA-A IL10
2 homeostasis/metabolism MP:0005376 9.9 CD36 CR2 CRP CSF2 DEK FCER2
3 immune system MP:0005387 9.7 CD36 CR2 CRP CSF2 FCER2 HLA-A
4 neoplasm MP:0002006 9.1 CSF2 DEK IL10 IL1R1 IL6 MIF

Drugs & Therapeutics for Juvenile Arthritis

Drugs for Juvenile Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
2
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Famotidine Approved Phase 4 76824-35-6 3325
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
6
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
7
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
8 Liver Extracts Phase 4
9 Anti-Ulcer Agents Phase 4
10 Antacids Phase 4
11 Proton Pump Inhibitors Phase 4
12 Histamine Antagonists Phase 4
13 Histamine H2 Antagonists Phase 4
14
Histamine Phosphate Phase 4 51-74-1 65513
15 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
16 Pharmaceutical Solutions Phase 4
17 Adrenergic alpha-Agonists Phase 4
18 Adrenergic Agents Phase 4
19 Hypnotics and Sedatives Phase 4
20 Adrenergic Agonists Phase 4
21 Analgesics, Non-Narcotic Phase 4
22 Analgesics Phase 4
23 Anti-Inflammatory Agents, Non-Steroidal Phase 4
24 Gastrointestinal Agents Phase 4
25 Anti-Infective Agents Phase 4
26
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
27
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
28
Infliximab Approved Phase 2, Phase 3 170277-31-3
29
Hydroxychloroquine Approved Phase 3 118-42-3 3652
30
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
31
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 54677470 5281106
32
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
33
Alendronate Approved Phase 2, Phase 3 66376-36-1, 121268-17-5 2088
34
Calcium carbonate Approved, Investigational Phase 3 471-34-1
35
Tofacitinib Approved, Investigational Phase 3 477600-75-2
36
Ibuprofen Approved Phase 3 15687-27-1 3672
37
Sodium citrate Approved, Investigational Phase 3 68-04-2
38
Mannitol Approved, Investigational Phase 3 69-65-8 6251 453
39
Adalimumab Approved Phase 3 331731-18-1 16219006
40
Certolizumab pegol Approved Phase 3 428863-50-7
41
Etanercept Approved, Investigational Phase 3 185243-69-0
42
leucovorin Approved Phase 3 58-05-9 6006 143
43
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
44
tannic acid Approved Phase 2, Phase 3 1401-55-4
45
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
46
Entecavir Approved, Investigational Phase 3 142217-69-4 153941
47
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
50
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 270)
# Name Status NCT ID Phase Drugs
1 Study of Therapeutic Effects and Side Effects of Leflunomide in Methotrexate Refractory Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
2 Pilot Study of the Safety and Efficacy of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Female Subjects With Juvenile Idiopathic Arthritis (JIA)/ Seronegative Arthritis Unknown status NCT00573651 Phase 4
3 When and in Whom to Stop Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept;etanercept
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis. Completed NCT00807846 Phase 4 Celecoxib;Naproxen
6 A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab Completed NCT01734382 Phase 4 Tocilizumab
7 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
8 Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA) Completed NCT00443430 Phase 4 methotrexate;methotrexate - etanercept - prednisolone arm
9 Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA Completed NCT00792233 Phase 4
10 A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA) Completed NCT01544114 Phase 4 VIMOVO 250/20;VIMOVO 375/20;VIMOVO 500/20
11 A Multicenter, Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Completed NCT01563185 Phase 4 800 mg ibuprofen/26.6 mg famotidine
12 Short and Long-term Immunogenicity and Safety Following the 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
13 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
14 Tocilizumab, An IL-6 Receptor Antibody, As Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT02034474 Phase 4 Tocilizumab;Placebo
15 A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis Recruiting NCT03301883 Phase 4 Tocilizumab;NSAIDs;CSs;MTX
16 Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population Recruiting NCT03069638 Phase 4 Dexmedetomidine;Sedatives/Hypnotics,Other
17 An Open Label Non-randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis Terminated NCT00637780 Phase 4 Sulfasalazine
18 Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
19 Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis Unknown status NCT00209469 Phase 2, Phase 3 alendronate sodium
20 The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Unknown status NCT00012506 Phase 3 TNFR:Fc
21 ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS) Completed NCT00339157 Phase 2, Phase 3 Anakinra
22 Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA) Completed NCT00775437 Phase 3 Adalimumab
23 A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis Who Have a History of an Inadequate Response or Intolerance to Methotrexate or Biologics Completed NCT01835470 Phase 3 Abatacept
24 Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From France Who Completed the Global, Multinational Trial (WA19977) Completed NCT01673919 Phase 3 tocilizumab [RoActemra/Actemra]
25 A Randomized, Double-blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Completed NCT00889863 Phase 3 canakinumab;placebo
26 An Open-Label, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With pJIA Completed NCT00144664 Phase 3 MRA(Tocilizumab)
27 A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA Completed NCT00144599 Phase 3 MRA(Tocilizumab);placebo
28 An Open-label, Single-arm, Active-treatment, Efficacy and Safety Study of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT02396212 Phase 3
29 Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global, Multinational Trial (WA19977) Completed NCT01667471 Phase 3 tocilizumab [RoActemra/Actemra]
30 Extension, Open-label, Interventional, Long-term Study to Evaluate the Safety of Tocilizumab Treatment in Patients From Brazil With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global Multinational Trial (WA19977) Completed NCT01727986 Phase 3 tocilizumab [RoActemra/Actemra]
31 Recombinant Human Growth Hormone Treatment in Juvenile Idiopathic Arthritis: Controlled Study on the Effect on Growth and Bone Development Completed NCT00420251 Phase 3 Genotropin
32 An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever Completed NCT00891046 Phase 3 Canakinumab
33 An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety, Efficacy and PK of MRA in Patients With pJIA Who Participated in Study MRA318JP Completed NCT00144625 Phase 3 MRA(Tocilizumab)
34 An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP Completed NCT00144612 Phase 3 MRA(Tocilizumab)
35 Randomized, Double-Blind, Multicenter, Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Completed NCT00652925 Phase 3 Celecoxib;Celecoxib;Naproxen
36 A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis Completed NCT00962741 Phase 3 Etanercept
37 A 24 Week Randomized, Double-blind, Placebo-controlled Withdrawal Trial With a 16 Week Open-label lead-in Phase, and 64 Week Open-label Follow-up, to Evaluate the Effect on Clinical Response and the Safety of Tocilizumab in Patients With Active Polyarticular-course Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
38 A Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis Completed NCT01166282 Phase 3
39 EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS Completed NCT02592434 Phase 3 CP-690,550 (tofacitinib)
40 A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab Completed NCT00642460 Phase 3 tocilizumab [RoActemra/Actemra];Placebo;Non-steroidal anti-inflammatory drugs (NSAIDs);methotrexate;corticosteroids
41 A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA) Completed NCT00095173 Phase 3 Abatacept;Placebo;Abatacept
42 β-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT02296424 Phase 3 ACZ885 150 mg (Canakinumab)
43 A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) Completed NCT02334748 Phase 3 canakinumab
44 Comparison of Anti-TNF Therapy Plus Methotrexate, Combination Therapy of DMARDs, and Methotrexate Alone in Very Early Polyarticular Juvenile Idiopathic Arthritis. A National Randomized Multicenter Clinical Trial. Completed NCT01015547 Phase 3 Infliximab plus methotrexate;Combination of DMARDs;Methotrexate alone
45 Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial Completed NCT01385826 Phase 2, Phase 3 Anti-tumor necrosis factor alpha monoclonal antibody;placebo
46 A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis. Completed NCT00279747 Phase 3 meloxicam 0.25 mg/kg;meloxicam 0.125 mg/kg;naproxen 10 mg/kg
47 WebSMART: Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis Completed NCT01541917 Phase 3
48 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis Completed NCT00048542 Phase 3 OLE BSA Adalimumab +/- MTX;OLE FD Adalimumab +/- MTX
49 Comparison of Iontophoresis of Lidocaine and Eutectic Mixture of Local Anesthetics (EMLA®) Cream Versus Subcutaneous Injections of Lidocaine and EMLA® for Pain Relief in Intra-articular Corticosteroid Injections in Children With Juvenile Idiopathic Arthritis: A Randomized Clinical Trial Completed NCT00465504 Phase 3
50 Immunogenicity and Duration of Immunity in Immunosuppressed Children Vaccinated With Quadrivalent HPV Vaccine Completed NCT02263703 Phase 3

Search NIH Clinical Center for Juvenile Arthritis

Cochrane evidence based reviews: arthritis, juvenile

Genetic Tests for Juvenile Arthritis

Anatomical Context for Juvenile Arthritis

MalaCards organs/tissues related to Juvenile Arthritis:

40
Bone, T Cells, Testes, Skin, Eye, Neutrophil, Monocytes

Publications for Juvenile Arthritis

Articles related to Juvenile Arthritis:

(show top 50) (show all 5867)
# Title Authors PMID Year
1
Biallelic loss-of-function LACC1/FAMIN Mutations Presenting as Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis. 61 56 6
30872671 2019
2
LACC1 Gene Defects in Familial Form of Juvenile Arthritis. 61 56 6
29717096 2018
3
Juvenile arthritis caused by a novel FAMIN (LACC1) mutation in two children with systemic and extended oligoarticular course. 56 6 61
27881174 2016
4
Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis. 6 61
25220867 2015
5
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. 56 61
14760812 2004
6
What is the real role of ultrasound in the management of juvenile idiopathic arthritis? 61 42
32060038 2020
7
Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial. 42 61
31842940 2019
8
Prolonged Fever, Diarrhea, Abdominal Pain, and Joint Pain in a 9-Year- Old Boy. 42
31810997 2020
9
Longitudinal Relationships Between Depression and Chronic Illness in Adolescents: An Integrative Review. 61
32171610 2020
10
Quality of life in children suffering from juvenile idiopathic arthritis-associated uveitis. 61
32088753 2020
11
Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. 61
32299797 2020
12
Current management of juvenile idiopathic arthritis affecting the craniovertebral junction. 61
31845026 2020
13
MTX intolerance in children and adolescents with juvenile idiopathic arthritis. 61
32259834 2020
14
Evaluation of ocular surface and meibomian glands in patients with uveitis related to oligoarticular juvenile idiopathic arthritis. 61
32270334 2020
15
Inflammatory manifestations in patients with Shwachman-Diamond syndrome: A novel phenotype. 61
32293785 2020
16
Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. 61
32277367 2020
17
Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study. 61
32417938 2020
18
Factors Predictive of Remission of Chronic Anterior Uveitis. 61
31932091 2020
19
Corneal endothelium in paediatric patients with uveitis: a prospective longitudinal study. 61
32522794 2020
20
Role of FDG-PET/CT in children with fever of unknown origin. 61
32030452 2020
21
Inflammatory Bowel Disease in Children with Systemic Juvenile Idiopathic Arthritis. 61
32541073 2020
22
Capturing the enthesitis related arthritis contemporary profile of Caucasian patients in the era of biologics. 61
32322980 2020
23
Systemic Treatment for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis. 61
32482885 2020
24
New medications are needed for children with juvenile idiopathic arthritis. 61
32524767 2020
25
Intestinal microbiota and juvenile idiopathic arthritis: current understanding and future prospective. 61
32533534 2020
26
Trochleitis presenting with double vision in a patient with juvenile idiopathic arthritis. 61
32498583 2020
27
Systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome due to a CASP1 variant causing inflammasome hyperactivation. 61
32556329 2020
28
Magnetic Resonance Imaging Followup of Temporomandibular Joint Inflammation, Deformation, and Mandibular Growth in Juvenile Idiopathic Arthritis Patients Receiving Systemic Treatment. 61
31523042 2020
29
The socio-material self-care practices of children living with hemophilia or juvenile idiopathic arthritis in Denmark. 61
32422525 2020
30
Gut microbiota in chronic inflammatory disorders: A focus on pediatric inflammatory bowel diseases and juvenile idiopathic arthritis. 61
32278875 2020
31
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. 61
32157555 2020
32
Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study. 61
32503658 2020
33
Orbital pseudotumor as the presenting symptom of Crohn's disease in a male child. 61
32215344 2020
34
Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases. 61
32557263 2020
35
Global prevalence estimates of three chronic musculoskeletal conditions: club foot, juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. 61
32532304 2020
36
Macrophage activation syndrome as a complication of dermatomyositis: A case report. 61
32548165 2020
37
Translating IL-6 biology into effective treatments. 61
32327746 2020
38
A Cross-Sectional Online Survey Identifies Subspecialty Differences in the Management of Pediatric Cataracts Associated with Uveitis. 61
32157612 2020
39
Periodic fever syndromes: a patient diagnosed with recurrent Kawasaki disease. 61
32524933 2020
40
Comorbidities in familial Mediterranean fever: analysis of 2000 genetically confirmed patients. 61
31598713 2020
41
Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases. 61
32514676 2020
42
Interleukin-1 Blockade in Systemic Juvenile Idiopathic Arthritis. 61
32291603 2020
43
Image guided sacroiliac joint corticosteroid injections in children: an 18-year single-center retrospective study. 61
32552835 2020
44
Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label Phase III study in Japanese patients. 61
32552266 2020
45
The Patient and Parent Perspective on Methotrexate in Recent Juvenile Idiopathic Arthritis Guidelines: Comment on the Article by Ringold et al. 61
32090463 2020
46
Impact of core stability exercises on bone mineralization and functional capacity in children with polyarticular juvenile idiopathic arthritis: a randomized clinical trial. 61
32514677 2020
47
Macrophage activation syndrome in juvenile dermatomyositis: a systematic review. 61
31529231 2020
48
Experience with Cidofovir as an adjunctive therapy in a patient of adenovirus-induced macrophage activation syndrome in systemic arthritis. 61
32418043 2020
49
Genetic diagnosis of autoinflammatory disease patients using clinical exome sequencing. 61
32222431 2020
50
Muscle function and architecture in children with juvenile idiopathic arthritis. 61
32420673 2020

Variations for Juvenile Arthritis

ClinVar genetic disease variations for Juvenile Arthritis:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 LACC1 NM_153218.4(LACC1):c.827del (p.Thr276fs)deletion Pathogenic 814022 13:44457992-44457992 13:43883856-43883856
2 LACC1 NM_153218.4(LACC1):c.3G>A (p.Met1Ile)SNV Pathogenic 814023 13:44455124-44455124 13:43880988-43880988
3 LACC1 NM_153218.4(LACC1):c.1240C>T (p.Arg414Ter)SNV Pathogenic 814024 13:44464356-44464356 13:43890220-43890220
4 LACC1 NM_153218.4(LACC1):c.988_990del (p.Ile330del)deletion Pathogenic 814025 rs776489319 13:44462973-44462975 13:43888837-43888839
5 LACC1 NM_153218.4(LACC1):c.128_129del (p.Cys43fs)deletion Pathogenic 814026 13:44455248-44455249 13:43881112-43881113
6 LACC1 NM_153218.4(LACC1):c.850T>C (p.Cys284Arg)SNV Likely pathogenic 180673 rs730880295 13:44458015-44458015 13:43883879-43883879

Expression for Juvenile Arthritis

Search GEO for disease gene expression data for Juvenile Arthritis.

Pathways for Juvenile Arthritis

Pathways related to Juvenile Arthritis according to KEGG:

36
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 JAK-STAT signaling pathway hsa04630

Pathways related to Juvenile Arthritis according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 MIF IL6 IL1R1 IL10 HLA-A H3C14
2
Show member pathways
13.08 IL6 IL1R1 IL10 HLA-A H3C14 FCER2
3
Show member pathways
12.8 IL6 IL1R1 HLA-A CXCL8 CSF2
4
Show member pathways
12.66 IL6 HLA-A FCER2 CXCL8 CR2
5 12.25 IL1R1 H3C14 CXCL8 CSF2
6
Show member pathways
12.19 MIF IL6 IL1R1 CXCL8
7 12.18 IL6 IL1R1 HLA-A CSF2
8
Show member pathways
12.13 IL6 IL10 HLA-A CXCL8
9 12.11 IL6 H3C14 CXCL8 CSF2
10 11.88 IL6 IL10 CXCL8
11 11.86 MIF IL6 IL1R1 CXCL8
12 11.82 IL6 IL10 CSF2 CD36
13 11.76 IL6 CXCL8 CSF2
14
Show member pathways
11.76 IL6 CXCL8 CSF2
15 11.71 IL6 IL10 FCER2 CXCL8 CD36
16 11.69 IL6 CXCL8 CSF2
17 11.64 IL6 IL10 CXCL8
18 11.62 IL6 IL10 CSF2
19 11.56 IL6 IL1R1 IL10 CXCL8 CSF2
20 11.52 IL6 CXCL8 CSF2
21
Show member pathways
11.5 MIF IL6 CXCL8 CSF2
22 11.43 IL6 IL1R1 FCER2 CSF2 CR2 CD36
23 11.37 IL6 IL10 CXCL8 CD36
24 11.15 IL6 IL10 CSF2
25 10.89 IL6 CXCL8 CRP
26 10.79 IL6 IL1R1 IL10 FCER2 CXCL8 CSF2

GO Terms for Juvenile Arthritis

Cellular components related to Juvenile Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 MIF IL6 IL10 CXCL8 CSF2 CRP
2 extracellular region GO:0005576 9.28 MIF IL6 IL1R1 IL10 H3C14 FCER2

Biological processes related to Juvenile Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.72 MIF IL6 IL1R1 CXCL8 CRP
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.61 MIF IL6 CD36
3 defense response to Gram-positive bacterium GO:0050830 9.56 IL6 HLA-A CRP CD36
4 immune response GO:0006955 9.56 IL6 IL1R1 IL10 HLA-A CXCL8 CSF2
5 cellular response to lipopolysaccharide GO:0071222 9.55 IL6 IL10 CXCL8 CSF2 CD36
6 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.46 CSF2 CD36
7 response to molecule of bacterial origin GO:0002237 9.4 IL10 CXCL8
8 negative regulation of lipid storage GO:0010888 9.37 IL6 CRP
9 cytokine-mediated signaling pathway GO:0019221 9.23 IL6 IL1RAPL2 IL1R1 IL10 FCER2 CXCL8

Molecular functions related to Juvenile Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 low-density lipoprotein particle binding GO:0030169 9.32 CRP CD36
2 NAD+ nucleotidase, cyclic ADP-ribose generating GO:0061809 9.26 IL1RAPL2 IL1R1
3 NAD(P)+ nucleosidase activity GO:0050135 9.16 IL1RAPL2 IL1R1
4 cytokine activity GO:0005125 9.02 MIF IL6 IL10 CXCL8 CSF2
5 interleukin-1 receptor activity GO:0004908 8.96 IL1RAPL2 IL1R1

Sources for Juvenile Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....